What Makes Biogen and Bristol-Myers Squibb Such Attractive Takeover Targets

  • Post author:
  • Post category:BioPharma

<IMG SRC"http://enewsletters.biospace.com/images/news/biospace-news-815x430-stock-positive.jpg" NAME"What Makes Biogen and Bristol-Myers Squibb Such Attractive Takeover Targets" ALT"What Makes Biogen and Bristol-Myers Squibb Such Attractive Takeover Targets"June 27, 2017By Mark Terry, BioSpace.com... Source: BioSpace

Continue ReadingWhat Makes Biogen and Bristol-Myers Squibb Such Attractive Takeover Targets

Merck & Co.'s Midas Touch Continues as Heart Drug Succeeds Where Pfizer, Eli Lilly and Roche's Failed

  • Post author:
  • Post category:BioPharma

<IMG SRC"http://enewsletters.biospace.com/images/news/biospace-news-815x450-merck.jpg" NAME"Merck's Midas Touch Continues as Heart Drug Succeeds Where Pfizer, Lilly and Roche's Failed" ALT"Merck's Midas Touch Continues as Heart Drug Succeeds Where Pfizer, Lilly and Roche's Failed"June…

Continue ReadingMerck & Co.'s Midas Touch Continues as Heart Drug Succeeds Where Pfizer, Eli Lilly and Roche's Failed

Bay Area's Portola Rockets as the FDA Approves First and Only Anticoagulant for Hospitals

  • Post author:
  • Post category:BioPharma

<IMG SRC"http://enewsletters.biospace.com/images/news/biospace-news-815x450-fda.jpg" NAME"Bay Area's Portola Rockets as the FDA Approves First and Only Anticoagulant for Hospitals" ALT"Bay Area's Portola Rockets as the FDA Approves First and Only Anticoagulant for Hospitals"June…

Continue ReadingBay Area's Portola Rockets as the FDA Approves First and Only Anticoagulant for Hospitals